A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug

Pharmaceutical Research

Volumn 21, Issue 12, 2004, Pages 2153-2157

  Stevens, Phillip J ^a   Sekido, Masaru ^a   Lee, Robert J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Folate receptor; Lipid nanoparticles; Lipophilic prodrug; Paclitaxel; Tumor targeting

Indexed keywords

DISTEAROYLPHOSPHATIDYLCHOLINE; FOLATE POLYETHYLENE GLYCOL CHOLESTEROL; FOLATE RECEPTOR; NANOPARTICLE; PACLITAXEL; PACLITAXEL 2' CARBONYL CHOLESTEROL; PACLITAXEL 7 CARBONYL CHOLESTEROL; PACLITAXEL DERIVATIVE; PRODRUG; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CIRCULATION; CONTROLLED STUDY; CYTOTOXICITY; DIAFILTRATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOPHILICITY; LUNG CARCINOMA; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHO CELLS; CRICETINAE; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; NANOSTRUCTURES; PACLITAXEL; PRODRUGS; RECEPTORS, CELL SURFACE;

EID: 17644366858     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-004-7667-5     Document Type: Article

References (31)

1. E. K. Rowinsky and R. C. Donehower. Paclitaxel (taxol). N. Engl. J. Med. 332:1004-1014 (1995).
2. A. K. Singla, A. Garg, and D. Aggarwal. Paclitaxel and its formulations. Int. J. Pharm. 235:179-192 (2002).
3. A. E. Sharma, E. Mayhew, L. Bolcsak, C. Cavanaugh, P. Harmon, A. Janoff, and R. J. Bernacki. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 71:103-107 (1997).
4. C. Bernsdorff, R. Reszka, and R. Winter. Interaction of the anticancer agent Taxol (paclitaxel) with phospholipid bilayers. J. Biomed. Mater. Res. 46:141-149 (1999).
5. P. Kan, Z. B. Chen, C. J. Lee, and I. M. Chu. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J. Control. Rel. 58:271-278 (1999).
6. P. P. Constantinides, K. J. Lambert, A. K. Tustian, B. Schneider. S. Lalji, W. Ma, B. Wentzel, D. Kessler, D. Worah, and S. C. Quay. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm. Res. 17:175-182 (2000).
7. W. C. Rose, B. H. Long, C. R. Fairchild, F. Y. Lee, and J. F. Kadow. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin. Can. Res. 7:2016-2021 (2001).
8. W. C. Rose, F. Y. Lee, J. Golik, and J. Kadow. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative. Cancer Chemother. Pharmacol. 46:246-250 (2000).
9. W. C. Rose, C. Fairchild, and F. Y. Lee. Preclinical antitumor activity of two novel taxanes. Cancer Chemother. Pharmacol. 47:97-105 (2001).
10. W. C. Rose, J. L. Clark, F. Y. Lee, and A. M Casazza. Preclinical antitumor activity of water-soluble paclitaxel derivatives. Cancer Chemother. Pharmacol. 39:486-492 (1997).
11. J. W. Lee, J. Y. Lu, P. S. Low, and P. L. Fuchs. Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics. Bioorg. Med. Chem. 10:2397-2414 (2002).
12. P. Rodrigues, K. Scheuermann, C. Stockmar, G. Maier, H. Fiebig, C. Unger, R. Mulhaupt, and F. Kratz. Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg. Med. Chem. Lett. 13:355-360 (2003).
13. J. W. Singer, B. Baker, P. De Vries, A. Kumar, S. Shaffer, E. Vawter, M. Bolton, and P. Garzone. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 519:81-99 (2003).
14. W. Wrasidlo, G. Gaedicke, R. K. Guy, J. Renaud, E. Pitsinos, K. C. Nicolaou, R. A. Reisfeld, and H. Lode. A novel 2′-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. Bioconjugate Chem. 13:1093-1099 (2002).
15. S. I. Sugahara, M. Kajiki, H. Kuriyama, and T. Kobayashi. Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol. Pharm. Bull. 25:632-641 (2002).
16. S. Ali, I. Ahmad, A. Peters, G. Master, S. Minchey, A. Janoff, and E. Mayhew. Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities. Anti-Cancer Drug 12:117-128 (2001).
17. G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli, and M. Boiocchi. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 74:193-198 (1997).
18. P. Garin-Chesa, I. Campbell, P. E. Saigo, J. L Lewis, L. J. Old, and W. J. Rettig. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 142:557-567 (1993).
19. W. J. Guo, J. Sudimack, and R. J. Lee. Receptor-specific delivery of liposomes via folate-PEG-chol. J. Liposome Res. 10:179-195 (2000).
20. P. J. Stevens and R. J. Lee. A folate receptor-targeted emulsion formulation for paclitaxel. Anticancer Res. 23:4927-4932 (2003).
21. T. Alien. Liposomal drug formulations, rationale for development and what we can expect for the future. Drugs 56:747-756 (1998).
22. B. B. Lundberg, V. Risovic, M. Ramaswamy, and K. M. Wasan. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J. Control. Rel. 86:93-100 (2003).
23. M. O. Bradley, N. L. Webb, F. H. Anthony, P. Devanesan, P. A. Witman, S. Hemamalini. M. C. Chander, S. D. Baker, L. He, S. B. Horwitz, and C. S. Swindell. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Cancer Res. 7:3229-3238 (2001).
24. A. Gabizon, A. T. Horowitz, D. Goren, D. Tzemach, F. Mandelbaum-Shavit, M. M. Qazen, and S. Zalipsky. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjugate Chem. 10:289-298 (1999).
25. R. J. Lee and P. S. Low. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233:134-144 (1995).
26. C. P. Leamon, I. Pastan, and P. S. Low. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J. Biol. Chem. 268:24847-24854 (1993).
27. C. P. Leamon and P. S. Low. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA 88:5572-5576 (1991).
28. X. Q. Pan, H. Wang, S. Shukla. M. Sekido. D. M. Adams. W. Tjarks, R. F. Earth, and R. J. Lee. Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy. Bioconjugate Chem. 13:435-442 (2002).
29. J. J. Sudimack, D. Adams, J. Rotaru, S. Shukla, J. Yan, M. Sekido, R. F. Earth, W. Tjarks, and R. J. Lee. Folate receptormediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy. Pharm. Res. 19:1502-1508 (2002).
30. A. Gabizon, H. Shmeeda, A. T. Horowitz, and S. Zalipsky. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Del. Rev. 56:1177-1192 (2004).
31. H. Hashizume, P. Baluk, S. Morikawa, J. W. McLean, G. Thruston, S. Roberge, R. K. Jain, and D. M. McDonald. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156:1363-1380 (2000).